A Novel Serum 4-microRNA Signature for Lung Cancer Detection

The aim of this study was to identify differentially-expressed miRNAs in the serum of non-small cell lung cancer (NSCLC) patients that might be a clinically-useful tool for lung cancer early detection. We performed miRNA expression profile analysis using TaqMan OpenArray Human panel in a discovery s...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 5; no. 1; p. 12464
Main Authors: Nadal, Ernest, Truini, Anna, Nakata, Asuka, Lin, Jules, Reddy, Rishindra M., Chang, Andrew C., Ramnath, Nithya, Gotoh, Noriko, Beer, David G., Chen, Guoan
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 23.07.2015
Nature Publishing Group
Subjects:
49/61
49/90
631/337/384/331
631/67/1612
692/53/2421
Aged
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Female
Humanities and Social Sciences
Humans
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Male
MicroRNAs - blood
MicroRNAs - classification
MicroRNAs - genetics
miRNA
multidisciplinary
Non-small cell lung carcinoma
Polymerase chain reaction
Reproducibility of Results
Science
Sensitivity and Specificity
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to identify differentially-expressed miRNAs in the serum of non-small cell lung cancer (NSCLC) patients that might be a clinically-useful tool for lung cancer early detection. We performed miRNA expression profile analysis using TaqMan OpenArray Human panel in a discovery set of 70 serum samples obtained at lung tumor resection and 22 non-cancer subjects (NC). Selected serum miRNAs were then validated by quantitative PCR using an independent validation set of serum samples from LC patients (n = 84) and NC (n = 23). Sixty miRNAs were significantly up-regulated and 31 were down-regulated in the serum from NSCLC patients versus NC (adjusted p  < 0.001). Four miRNAs (miR-193b, miR-301, miR-141 and miR-200b) were selected for validating their diagnostic value in an independent cohort. In the discovery set, the ROC plot derived from the combination of these miRNAs yielded an area under the curve (AUC) of 0.985 (95% CI 0.961–1.000, p  < 0.001). In the test set, this miRNA signature exhibited an AUC of 0.993 (95% CI 0.979–1.000, p  < 0.001). In conclusion, we identified a serum 4-miRNA signature that discriminated with high accuracy lung cancer patients from NC. Further prospective validation of this miRNA signature is warranted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/srep12464